VRTX ROE | VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

VERTEX PHARMACEUTICALS INC / MA roe for the quarter ending 2026-06-30 was 21.76%, a 2.73% increase year-over-year.
VERTEX PHARMACEUTICALS INC / MA roe for the quarter ending 2026-03-31 was 22.41%, a change of 28.40% year-over-year.
VERTEX PHARMACEUTICALS INC / MA roe for the quarter ending 2025-12-31 was 21.18%, a change of 24.44% year-over-year.
VERTEX PHARMACEUTICALS INC / MA roe for the quarter ending 2025-09-30 was 21.22%, a change of 24.29% year-over-year.
VERTEX PHARMACEUTICALS INC / MA roe for fiscal 2025 was 21.18%, a change of 24.44% from fiscal 2024.
VERTEX PHARMACEUTICALS INC / MA roe for fiscal 2024 was -3.26%, a 115.85% decline from fiscal 2023.
VERTEX PHARMACEUTICALS INC / MA roe for fiscal 2023 was 20.59%, a 13.77% decline from fiscal 2022.
VERTEX PHARMACEUTICALS INC / MA roe for fiscal 2022 was 23.88%, a 2.97% increase from fiscal 2021.

Available history: 2010-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical ROE

Date	ROE	Net income 12 month	Net income 3 month	Shareholder equity
2026-06-30	21.76%	$4.41B	$1.10B	$20.25B
2026-03-31	22.41%	$4.34B	$1.03B	$19.36B
2025-12-31	21.18%	$3.95B	$1.19B	$18.67B
2025-09-30	21.22%	$3.68B	$1.08B	$17.32B
2025-06-30	21.18%	$3.64B	$1.03B	$17.18B
2025-03-31	-5.99%	-$988.9M	$646.30M	$16.5B
2024-12-31	-3.26%	-$535.6M	$913.00M	$16.41B
2024-09-30	-3.07%	-$479.8M	$1.05B	$15.63B
2024-06-30	-3.32%	-$489.9M	-$3.59B	$14.77B
2024-03-31	21.67%	$4.02B	$1.10B	$18.55B
2023-12-31	20.59%	$3.62B	$968.80M	$17.58B
2023-09-30	21.01%	$3.47B	$1.04B	$16.51B
2023-06-30	21.75%	$3.36B	$915.70M	$15.47B
2023-03-31	22.59%	$3.26B	$699.80M	$14.43B
2022-12-31	23.88%	$3.32B	$818.90M	$13.91B
2022-09-30	25.12%	$3.27B	$930.50M	$13.03B
2022-06-30	26.77%	$3.19B	$810.50M	$11.93B
2022-03-31	22.47%	$2.45B	$762.10M	$10.91B
2021-12-31	23.19%	$2.34B	$770.10M	$10.1B
2021-09-30	22.83%	$2.18B	$851.90M	$9.53B
2021-06-30	21.66%	$1.99B	$67.00M	$9.2B
2021-03-31	30.76%	$2.76B	$653.10M	$8.98B
2020-12-31	31.22%	$2.71B	$604.19M	$8.69B
2020-09-30	33.08%	$2.69B	$667.43M	$8.13B
2020-06-30	27.67%	$2.08B	$837.27M	$7.52B
2020-03-31	23.38%	$1.51B	$602.75M	$6.46B
2019-12-31	19.34%	$1.18B	$583.23M	$6.09B
2019-09-30	40.81%	$2.14B	$57.52M	$5.25B
2019-06-30	43.70%	$2.22B	$267.43M	$5.07B
2018-12-31	47.28%	$2.1B	$1.55B	$4.44B
2018-09-30	22.27%	$647.05M	$128.75M	$2.91B
2018-06-30	15.46%	$415.36M	$207.36M	$2.69B
2018-03-31	9.41%	$225.99M	$210.26M	$2.4B
2017-12-31	12.99%	$263.48M	$100.68M	$2.03B
2017-09-30	10.93%	$195.75M	-$102.95M	$1.79B
2017-06-30	15.55%	$259.86M	$18.00M	$1.67B
2017-03-31	11.82%	$177.34M	$247.76M	$1.5B
2016-12-31	-9.69%	-$112.05M	$32.95M	$1.16B
2016-09-30	-21.41%	-$218.73M	-$38.84M	$1.02B
2016-06-30	-28.03%	-$275.04M	-$64.53M	$981.35M
2016-03-31	-41.73%	-$399.36M	-$41.63M	$957.08M
2015-12-31	-59.19%	-$556.33M	-$73.73M	$939.97M
2015-09-30	-71.49%	-$659.26M	-$95.15M	$922.15M
2015-06-30	-82.03%	-$734.17M	-$188.85M	$894.96M
2015-03-31	-72.17%	-$704.7M	-$198.61M	$976.46M
2014-12-31	-68.70%	-$738.56M	-$176.66M	$1.08B
2014-09-30	-44.78%	-$517.61M	-$170.06M	$1.16B
2014-06-30	-40.24%	-$471.69M	-$159.38M	$1.17B
2014-03-31	-30.02%	-$369.47M	-$232.46M	$1.23B
2013-12-31	-32.81%	-$445.03M	$44.28M	$1.36B
2013-09-30	-44.70%	-$565.46M	-$124.13M	$1.26B
2013-06-30	-37.72%	-$498.87M	-$57.16M	$1.32B
2013-03-31	-67.90%	-$506.64M	-$308.02M	$746.12M
2012-12-31	-10.71%	-$107.03M	-$76.15M	$999.18M
2012-09-30	12.43%	$127.75M	-$57.54M	$1.03B
2012-06-30	39.16%	$406.4M	-$64.93M	$1.04B
2012-03-31	31.95%	$297.26M	$91.59M	$930.5M
2011-12-31	3.76%	$29.57M	$158.63M	$786.84M
2011-09-30	-53.37%	-$309.45M	$221.11M	$579.76M
2011-06-30	-240.45%	-$739.51M	-$174.07M	$307.55M

Annual ROE

Date	ROE	Net income 12 month	Shareholder equity
2025-12-31	21.18%	$3.95B	$18.67B
2024-12-31	-3.26%	-$535.6M	$16.41B
2023-12-31	20.59%	$3.62B	$17.58B
2022-12-31	23.88%	$3.32B	$13.91B
2021-12-31	23.19%	$2.34B	$10.1B
2020-12-31	31.22%	$2.71B	$8.69B
2019-12-31	19.34%	$1.18B	$6.09B
2018-12-31	47.28%	$2.1B	$4.44B
2017-12-31	12.99%	$263.48M	$2.03B
2016-12-31	-9.69%	-$112.05M	$1.16B
2015-12-31	-59.19%	-$556.33M	$939.97M
2014-12-31	-68.70%	-$738.56M	$1.08B
2013-12-31	-32.81%	-$445.03M	$1.36B
2012-12-31	-10.71%	-$107.03M	$999.18M
2011-12-31	3.76%	$29.57M	$786.84M
2010-12-31	-149.74%	-$754.63M	$503.97M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
PFIZER INC (PFE)	United States	$162.042B	31.94
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64